Orum Therapeutics
Orum Therapeutics has 1 licensing announcement in this dataset, dated 2024-07-16.
- Country / operating region
- South Korea
- Ticker
- 475830.KQ
- Headquarters
- 查無
- Founded
- 查無
- Business
- Biopharmaceutical research and development
- Website
- www.orumrx.com
Pipeline / products
| Asset / platform | Target | Modality | Stage at announcement | Announcement date |
|---|---|---|---|---|
| TPD2 degrader-antibody conjugate platform | 查無 | 查無 | 查無 | 2024-07-16 |
| Asset | Registered / announced phase | Trial | Status | Sponsor | Record date |
|---|---|---|---|---|---|
| TPD2 degrader-antibody conjugate platform | 查無 | — | 查無 | 查無 | 2024-07-16 |
Licensing deals
| Date | Counterparty | Asset / platform | Upfront | Near-term | Milestones | Potential total | Other disclosed terms |
|---|---|---|---|---|---|---|---|
| 2024-07-16 | Vertex Pharmaceuticals | TPD2 degrader-antibody conjugate platform | USD 15m | 查無 | 查無 | 查無 | Option fees + milestones per target ≤ USD 310m Option fees and milestones are capped per target for up to three targets; an aggregate maximum is not assigned. |
| Counterparty | Territory | Royalties |
|---|---|---|
| Vertex Pharmaceuticals | Worldwide | Tiered royalties on future global annual net sales. |
Catalysts
查無
Latest monthly revenue
查無
Most advanced drug
查無
Drugnews analysis
查無